{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:13:58Z","timestamp":1793812438429,"version":"4.6.1"},"reference-count":39,"publisher":"American Society of Hematology","issue":"15","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Ivosidenib is a first-in-class mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor with efficacy and tolerability in patients with advanced mIDH1 hematologic malignancies, leading to approval in frontline and relapsed\/refractory (R\/R) mIDH1 acute myeloid leukemia. We report final data from a phase 1 single-arm substudy of once-daily ivosidenib in patients with R\/R mIDH1 myelodysplastic syndrome (MDS) after failure of standard-of-care therapies. Primary objectives were to determine safety, tolerability, and clinical activity. The primary efficacy end point was the complete remission (CR)\u00a0+ partial remission (PR) rate. Nineteen patients were enrolled; 18 were included in the efficacy analysis. Treatment-related adverse events occurred in 8 (42.1%) patients, including a grade 1 QT interval prolongation in 1 (5.3%) patient and grade 2 differentiation syndrome in 2 (10.5%) patients. Rates of CR\u00a0+ PR and objective response (CR\u00a0+ PR\u00a0+ marrow CR) were 38.9% (95% confidence interval [CI], 17.3-64.3) and 83.3% (95%\u00a0CI, 58.6-96.4), respectively. Kaplan-Meier estimates showed a 68.6% probability of patients in CR achieving a remission duration of \u22655 years, and a median overall survival of 35.7\u00a0months. Of note, 71.4% and 75.0% baseline red blood cell (RBC)- and platelet-transfusion-dependent patients, respectively, became transfusion independent (TI; no transfusion for \u226556\u00a0days); 81.8% and 100% of baseline RBC and platelet TI patients, respectively, remained TI. One (5.3%) patient proceeded to a hematopoietic stem cell transplant. In conclusion, ivosidenib is clinically active, with durable remissions and a manageable safety profile observed in these patients. This trial was registered at www.ClinicalTrials.gov as #NCT02074839.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012302","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T14:08:48Z","timestamp":1713535728000},"page":"4209-4220","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":53,"title":["Final phase 1 substudy results of ivosidenib for patients with mutant\n                    <i>IDH1<\/i>\n                    relapsed\/refractory myelodysplastic syndrome"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"first","affiliation":[{"name":"1Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0384-3658","authenticated-orcid":false,"given":"Gail J.","family":"Roboz","sequence":"additional","affiliation":[{"name":"2Clinical and Translational Leukemia Programs, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Watts","sequence":"additional","affiliation":[{"name":"3Division of Hematology, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9573-2690","authenticated-orcid":false,"given":"Yazan F.","family":"Madanat","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle T.","family":"Prince","sequence":"additional","affiliation":[{"name":"5Division of Hematologic Malignancy, Johns Hopkins Hospital, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3129-9047","authenticated-orcid":false,"given":"Praneeth","family":"Baratam","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Oncology, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8126-4942","authenticated-orcid":false,"given":"St\u00e9phane","family":"de Botton","sequence":"additional","affiliation":[{"name":"7Hematologie Clinique, Institut Gustave Roussy, Villejuif, Facult\u00e9 Paris-Saclay, Institut Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Stein","sequence":"additional","affiliation":[{"name":"8Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Foran","sequence":"additional","affiliation":[{"name":"9Division of Hematology & Medical Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha L.","family":"Arellano","sequence":"additional","affiliation":[{"name":"10Department of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0504-8233","authenticated-orcid":false,"given":"David A.","family":"Sallman","sequence":"additional","affiliation":[{"name":"11Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Hossain","sequence":"additional","affiliation":[{"name":"12Servier Pharmaceuticals, LLC, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan M.","family":"Marchione","sequence":"additional","affiliation":[{"name":"12Servier Pharmaceuticals, LLC, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Bai","sequence":"additional","affiliation":[{"name":"12Servier Pharmaceuticals, LLC, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prapti A.","family":"Patel","sequence":"additional","affiliation":[{"name":"12Servier Pharmaceuticals, LLC, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Kapsalis","sequence":"additional","affiliation":[{"name":"12Servier Pharmaceuticals, LLC, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4907-6447","authenticated-orcid":false,"given":"Amir T.","family":"Fathi","sequence":"additional","affiliation":[{"name":"13Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"issue":"1","key":"2024081315203503900_bib1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/ajh.24253","article-title":"Myelodysplastic syndromes: contemporary review and how we treat","volume":"91","author":"Gangat","year":"2016","journal-title":"Am J Hematol"},{"issue":"19","key":"2024081315203503900_bib2","doi-asserted-by":"crossref","first-page":"10232","DOI":"10.3390\/ijms221910232","article-title":"Molecular targeted therapy and immunotherapy for myelodysplastic syndrome","volume":"22","author":"Lee","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2024081315203503900_bib3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ajh.23454","article-title":"Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes","volume":"88","author":"Mishra","year":"2013","journal-title":"Am J Hematol"},{"issue":"7","key":"2024081315203503900_bib4","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"3","key":"2024081315203503900_bib5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41591-022-01696-4","article-title":"Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy","volume":"28","author":"Ganan-Gomez","year":"2022","journal-title":"Nat Med"},{"issue":"suppl","key":"2024081315203503900_bib6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/HS9.0000000000000219","article-title":"High-risk MDS after HMAs","volume":"3","author":"Ades","year":"2019","journal-title":"Hemasphere"},{"issue":"24","key":"2024081315203503900_bib7","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Prebet","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024081315203503900_bib8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/cncr.29145","article-title":"Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium","volume":"121","author":"Jabbour","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"2024081315203503900_bib9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/leu.2016.275","article-title":"Isocitrate dehydrogenase mutations in myeloid malignancies","volume":"31","author":"Medeiros","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"2024081315203503900_bib10","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/leu.2015.211","article-title":"IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression","volume":"30","author":"DiNardo","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"2024081315203503900_bib11","doi-asserted-by":"crossref","first-page":"e100206","DOI":"10.1371\/journal.pone.0100206","article-title":"Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis","volume":"9","author":"Jin","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"2024081315203503900_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000479546","article-title":"IDH1 mutation is an independent inferior prognostic indicator for patients with myelodysplastic syndromes","volume":"138","author":"Wang","year":"2017","journal-title":"Acta Haematol"},{"issue":"10","key":"2024081315203503900_bib13","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2024081315203503900_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-8722-5-5","article-title":"Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients","volume":"5","author":"Chotirat","year":"2012","journal-title":"J\u00a0Hematol Oncol"},{"issue":"7274","key":"2024081315203503900_bib15","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"issue":"7390","key":"2024081315203503900_bib16","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"issue":"21","key":"2024081315203503900_bib17","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1182\/blood.V124.21.3734.3734","article-title":"AG-120, an oral, selective, first-in-class, potent inhibitor of mutant IDH1, reduces intracellular 2HG and induces cellular differentiation in TF-1 R132H cells and primary human IDH1 mutant AML patient samples treated ex\u00a0vivo","volume":"124","author":"Hansen","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2024081315203503900_bib18","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","article-title":"Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers","volume":"9","author":"Popovici-Muller","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"2024081315203503900_bib19","unstructured":"US Food and Drug Administration\n          . FDA Approves Ivosidenib As First-Line Treatment for AML with IDH1 Mutation. Accessed 5 January 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ivosidenib-first-line-treatment-aml-idh1-mutation."},{"key":"2024081315203503900_bib20","unstructured":"US Food and Drug Administration\n          . FDA Approves Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. Accessed 5 January 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ivosidenib-combination-azacitidine-newly-diagnosed-acute-myeloid-leukemia."},{"key":"2024081315203503900_bib21","unstructured":"US Food and Drug Administration\n          . FDA Approves Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia. Accessed 5 January 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ivosidenib-relapsed-or-refractory-acute-myeloid-leukemia."},{"key":"2024081315203503900_bib22","unstructured":"US Food and Drug Administration\n          . FDA Approves Ivosidenib for Myelodysplastic Syndromes. Accessed 4 January 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ivosidenib-myelodysplastic-syndromes."},{"issue":"25","key":"2024081315203503900_bib23","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"16 suppl","key":"2024081315203503900_bib24","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.1200\/JCO.2022.40.16_suppl.7053","article-title":"Ivosidenib in patients with IDH1-mutant relapsed\/refractory myelodysplastic syndrome (R\/R MDS): updated enrollment and results of a phase 1 dose-escalation and expansion substudy","volume":"40","author":"Sallman","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2024081315203503900_bib25","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1182\/blood-2019-123946","article-title":"Ivosidenib (AG-120) in patients with IDH1-mutant relapsed\/refractory myelodysplastic syndrome: updated enrollment of a phase 1 Dose Escalation and Expansion Study","volume":"134","author":"Foran","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2024081315203503900_bib26","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"7","key":"2024081315203503900_bib27","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"key":"2024081315203503900_bib28","author":"Tibsova (ivosidenib)","year":"2018"},{"issue":"6","key":"2024081315203503900_bib29","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2024081315203503900_bib30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.leukres.2012.01.006","article-title":"The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes","volume":"36","author":"Platzbecker","year":"2012","journal-title":"Leuk Res"},{"issue":"6","key":"2024081315203503900_bib31","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.1097\/HS9.0000000000000314","article-title":"Treatment of anemia in transfusion-dependent and non-transfusion-dependent lower-risk MDS: current and emerging strategies","volume":"3","author":"Germing","year":"2019","journal-title":"Hemasphere"},{"key":"2024081315203503900_bib32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1477-7525-7-81","article-title":"Valuation of transfusion-free living in MDS: results of health utility interviews with patients","volume":"7","author":"Szende","year":"2009","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"2024081315203503900_bib33","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/cncr.21860","article-title":"Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life","volume":"106","author":"Balducci","year":"2006","journal-title":"Cancer"},{"issue":"10","key":"2024081315203503900_bib34","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3324\/haematol.2010.025494","article-title":"IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis","volume":"95","author":"Thol","year":"2010","journal-title":"Haematologica"},{"issue":"21","key":"2024081315203503900_bib35","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1182\/bloodadvances.2020001528","article-title":"Outcome of patients with IDH1\/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors","volume":"4","author":"Chifotides","year":"2020","journal-title":"Blood Adv"},{"key":"2024081315203503900_bib36","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1016\/S2152-2650(22)01413-6","article-title":"MDS-431 outcomes of transformation to acute myeloid leukemia after hypomethylating agent therapy in patients with myelodysplastic syndromes","volume":"22","author":"Kim","year":"2022","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"5","key":"2024081315203503900_bib37","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00280-020-04064-6","article-title":"Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation","volume":"85","author":"Fan","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"issue":"24","key":"2024081315203503900_bib38","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1182\/blood-2013-03-493197","article-title":"Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia","volume":"121","author":"DiNardo","year":"2013","journal-title":"Blood"},{"issue":"suppl 1","key":"2024081315203503900_bib39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2021-146932","article-title":"Ivosidenib monotherapy is effective in patients with IDH1 mutated myelodysplastic syndrome (MDS): the Idiome phase 2 study by the GFM Group","volume":"138","author":"Sebert","year":"2021","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/15\/4209\/2237909\/blooda_adv-2023-012302-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/15\/4209\/2237909\/blooda_adv-2023-012302-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T11:22:13Z","timestamp":1723548133000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/15\/4209\/515789\/Final-phase-1-substudy-results-of-ivosidenib-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":39,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,8,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012302","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]}}}